Knowledge of tumor/blood genomic testing (NGS) and ESR1 mutations in a survey of patients with ER+/HER2-metastatic breast cancer (mBC)

被引：0
|
作者：
Meisel, Jane
Sammons, Sarah L.
Shanahan, Kelly
Pluard, Timothy
Kozlowski, Monica
Carroll, Dominic
Attias, Elizabeth
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 05期
关键词：
D O I：
10.1158/1538-7445.SABCS22-P6-09-02
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P6-09-02
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Tumor-agnostic measurement of ctDNA levels in first line ER+, HER2-metastatic breast cancer patients as a marker for survival
    Verschoor, Noortje
    Kraan, Jaco
    de Weerd, Vanja
    Van, Ngoc M.
    Jager, Agnes
    Sleijfer, Stefan
    Martens, John Wm
    Wilting, Saskia M.
    CANCER RESEARCH, 2023, 83 (05)
  • [22] ERα dysfunction caused by ESR1 mutations and therapeutic pressure promotes lineage plasticity in ER+ breast cancer
    Jackson Liang
    Xiaosai Yao
    Patrick Aouad
    Bu-Er Wang
    Lisa Crocker
    Subhra Chaudhuri
    Yuxin Liang
    Spyros Darmanis
    Jennifer Giltnane
    Heather M. Moore
    Junko Aimi
    Ching-Wei Chang
    Mary R. Gates
    Jennifer Eng-Wong
    Marc Hafner
    Ciara Metcalfe
    Nature Cancer, 2025, 6 (2) : 357 - 371
  • [23] Genomic Landscape of ER+/HER2-metastatic breast cancer as a function of prior treatment with a CDK4/6 inhibitor
    Chica-Parrado, M. Rosario
    Chica-Parrado, M. Rosario
    Lin, Chang-Ching
    Mahoney, Timothy
    Mauer, Elizabeth
    Hanker, Ariella
    Arteaga, Carlos
    CANCER RESEARCH, 2023, 83 (05)
  • [24] ESR1 Mutations in Circulating Plasma Tumor DNA from Metastatic Breast Cancer Patients
    Chu, David
    Paoletti, Costanza
    Gersch, Christina
    VanDenBerg, Dustin A.
    Zabransky, Daniel J.
    Cochran, Rory L.
    Wong, Hong Yuen
    Toro, Patricia Valda
    Cidado, Justin
    Croessmann, Sarah
    Erlanger, Bracha
    Cravero, Karen
    Kyker-Snowman, Kelly
    Button, Berry
    Parsons, Heather A.
    Dalton, W. Brian
    Gillani, Riaz
    Medford, Arielle
    Aung, Kimberly
    Tokudome, Nahomi
    Chinnaiyan, Arul M.
    Schott, Anne
    Robinson, Dan
    Jacks, Karen S.
    Lauring, Josh
    Hurley, Paula J.
    Hayes, Daniel F.
    Rae, James M.
    Park, Ben Ho
    CLINICAL CANCER RESEARCH, 2016, 22 (04) : 993 - 999
  • [25] Lasofoxifene (LAS) plus abemaciclib (Abema) for treating ESR1-mutated ER+/HER2-metastatic breast cancer (mBC) after progression on prior therapies: ELAINE 2 study update
    Damodaran, Senthil
    Moore, Halle C. F.
    Anderson, Ian Churchill
    Cherian, Mathew Amprayil
    O'Sullivan, Ciara Catherine
    Plourde, Paul V.
    Portman, David Jay
    Goetz, Matthew P.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [26] ESR1 mutations emerging during neoadjuvant endocrine therapy in postmenopausal ER+/HER2-early breast cancer patients: prevalence and prognostic impact
    Sandoval, Jose Luis
    Salaun, Helene
    Renault, Shufang
    Carausu, Marcela
    Rampanou, Aurore
    Hego, Caroline
    Carton, Matthieu
    Cabel, Luc
    Pierga, Jean-Yves
    Geiss, Romain
    Bidard, Francois-Clement
    Lerebours, Florence
    CANCER RESEARCH, 2024, 84 (09)
  • [27] Assessment of ESR1 and ERBB2 mutations in estrogen receptor positive (ER plus ) metastatic breast cancers (MBC).
    Basu, Gargi D.
    White, Tracey
    LoBello, Janine R.
    Kurdoglu, Ahmet
    Trent, Jeffrey M.
    Halbert, Matthew J.
    Royce, Thomas
    O'Shaughnessy, Joyce
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [28] Primary endocrine resistance of ER+ breast cancer with ESR1 mutations interrogated by droplet digital PCR
    Ahn, Sung Gwe
    Bae, Soong June
    Kim, Yoonjung
    Ji, Jung Hwan
    Chu, Chihhao
    Kim, Dooreh
    Lee, Janghee
    Cha, Yoon Jin
    Lee, Kyung-A
    Jeong, Joon
    NPJ BREAST CANCER, 2022, 8 (01)
  • [29] Primary endocrine resistance of ER+ breast cancer with ESR1 mutations interrogated by droplet digital PCR
    Sung Gwe Ahn
    Soong June Bae
    Yoonjung Kim
    Jung Hwan Ji
    Chihhao Chu
    Dooreh Kim
    Janghee Lee
    Yoon Jin Cha
    Kyung-A Lee
    Joon Jeong
    npj Breast Cancer, 8
  • [30] PYTHIA: A phase II study of palbociclib plus fulvestrant for pretreated patients with ER+/HER2-metastatic breast cancer
    Zardavas, D.
    Regan, M.
    Maibach, R.
    Ruepp, B.
    Hiltbrunner, A.
    Blacher, L.
    Gelber, R.
    Gebhart, G.
    Di Leo, A.
    Hilbers, F.
    Colleoni, M.
    Zoppoli, G.
    Bertelli, G.
    Bliss, J.
    Duhoux, F.
    Piccart, M.
    Malorni, L.
    ANNALS OF ONCOLOGY, 2017, 28
12345